Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ellenberg S., Hamilton J. M. Surrogate endpoints in clinical trials: cancer. Stat Med. 1989 Apr;8(4):405–413. doi: 10.1002/sim.4780080404. [DOI] [PubMed] [Google Scholar]
- Fischl M. A., Richman D. D., Hansen N., Collier A. C., Carey J. T., Para M. F., Hardy W. D., Dolin R., Powderly W. G., Allan J. D. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med. 1990 May 15;112(10):727–737. doi: 10.7326/0003-4819-112-10-727. [DOI] [PubMed] [Google Scholar]
- Hillis A., Seigel D. Surrogate endpoints in clinical trials: ophthalmologic disorders. Stat Med. 1989 Apr;8(4):427–430. doi: 10.1002/sim.4780080406. [DOI] [PubMed] [Google Scholar]
- Machado S. G., Gail M. H., Ellenberg S. S. On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection. J Acquir Immune Defic Syndr. 1990;3(11):1065–1073. [PubMed] [Google Scholar]
- Volberding P. A., Lagakos S. W., Koch M. A., Pettinelli C., Myers M. W., Booth D. K., Balfour H. H., Jr, Reichman R. C., Bartlett J. A., Hirsch M. S. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990 Apr 5;322(14):941–949. doi: 10.1056/NEJM199004053221401. [DOI] [PubMed] [Google Scholar]
- Wittes J., Lakatos E., Probstfield J. Surrogate endpoints in clinical trials: cardiovascular diseases. Stat Med. 1989 Apr;8(4):415–425. doi: 10.1002/sim.4780080405. [DOI] [PubMed] [Google Scholar]